ArticleDrugs in R&D2015
Auranofin: repurposing an old drug for a golden new age.
Article in Drugs in R&D, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
220 citing papers in PubMed, 1 synthesis or guideline pooled it, 492 citations in OpenAlex.
- Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials.Nutrients · 2024Pooled it
- Gene regulatory network analysis identifies auranofin as an anti-atherosclerotic drug.Nature communications · 2026Article
- Multifunctional auranofin analogues: dual-targeting TSPO/TrxR gold(I) complexes with activity in resistant ovarian cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Tuning Au Reactivity Beyond Canonical Targets: Ligand-Driven Au(I) Metalation of Lysine Residues in Hen Egg White Lysozyme.Inorganic chemistry · 2026Article
- From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study.Journal of clinical periodontology · 2026Article
- In Vitro Cytochrome P450 Interaction Profile and ADME Characterisation of Gold(I)-Triphenylphosphine Complexes with 6-Alkoxy-9-deazapurine Ligands.Pharmaceutics · 2026Article
- Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target.Pharmacological reports : PR · 2026Review
- Auranofin reimagined: an emerging therapeutic candidate for neurodegenerative diseases through molecular mechanistic insights.Inflammopharmacology · 2026Review
- Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants.Scientific reports · 2026Article
- Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds.Neuro-oncology · 2026Article
- Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.International journal of molecular sciences · 2026Article
- Auranofin Combination Therapy: A New Frontier in Cancer Treatment.Molecules (Basel, Switzerland) · 2026Review
- Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes.Biomolecules · 2026Article
- Anti-staphylococcal activity of the auranofin-analogous PEtFrontiers in cellular and infection microbiology · 2026Article
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells.Cell death discovery · 2025Article
- Synthesis and in vitro characterization of [EJNMMI radiopharmacy and chemistry · 2025Article
- Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Repurposing medications to prevent psychosis.Npj mental health research · 2025Review
160 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery, development and registration is an expensive and time-consuming process associated with a high failure rate [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Woodcock and Woosley (Annu Rev Med 59:1-12, 2008)]. Drug 'repurposing' is the identification of new therapeutic purposes for already approved drugs and is more affordable and achievable than novel drug discovery [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013)]. Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)]. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes that are essential for maintaining intracellular levels of reactive oxygen species. Inhibition of these enzymes leads to cellular oxidative stress and intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Fan et al. (Cell Death Dis 5:e1191, 2014), Fiskus et al. (Cancer Res 74:2520-2532, 2014), Marzano et al. (Free Radic Biol Med 42:872-881, 2007)]. Drugs such as auranofin that have already been approved for human use [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)] can be brought into clinical use for other diseases relatively quickly and for a fraction of the cost of new drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.